Introduction
The worldwide incidence of infections caused by pneumococci resistant to penicillin G and other antimicrobial agents has increased at an alarming rate during the past two decades, particularly in the past five years. 1, 2 The main known foci of penicillin-resistant pneumococci are currently South Africa, Spain, Eastern Europe and parts of Asia. However, wherever susceptibility testing is performed by appropriate methods, resistant strains are almost universally found. 1 The spread of penicillinresistant clones from country to country and from continent to continent demonstrates the capability of these strains to spread rapidly throughout the world. 3, 4 In the USA, recent surveys have shown an increase in resistance to penicillin from <5% before 1989 (including <0.02% of isolates with MICs 2.0 mg/L) to 6.6% in 1991-1992 (with 1.3% of isolates with MICs 2.0 mg/L). 5, 6 A recent report from metropolitan Atlanta has documented an incidence of clinical isolates of resistant pneumococci of 25% in children between January and October 1994. 7 There is currently no standardized oral therapy for infections such as otitis media caused by penicillin-intermediate and -resistant pneumococci.
8-11 Block and coworkers have recently reported a 28% incidence rate of penicillin-resistant pneumococci from middle ear fluid of children with acute otitis media in Kentucky, and a 29% incidence level of these strains in nasopharyngeal cultures from children with otitis media in Tennessee. 12 There is an urgent need for oral -lactams which can be used for outpatient treatment of infections such as pneumonia, bronchitis, sinusitis and otitis media caused by penicillin-intermediate and -resistant pneumococci. Previous studies have documented good activity of cefditoren, a new oral cephalosporin in pivaloyloxymethyl ester form, against penicillin-susceptible and -resistant pneumococci, with all cefditoren MICs 2.0 mg/L, even against pneumococci fully resistant to penicillin. 13 Other
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Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other -lactams © 1997 The British Society for Antimicrobial Chemotherapy JAC oral cephalosporins have much higher MICs against these strains, with cefdinir, cefuroxime and cefpodoxime having the lowest MICs for the group. Amoxycillin has lower MICs than those of penicillin G, ampicillin and all oral cephalosporins except cefditoren against these strains. WY-49605, a new broad-spectrum penem, yields MICs one or two dilutions lower than those of amoxycillin against penicillin-susceptible and -resistant pneumoc o c c i .
The current study confirms and extends these findings by examining the activity of penicillin G, ampicillin, amoxycillin, WY-49605, cefditoren, cefuroxime, cefpodoxime, cefdinir, cefixime and cefaclor by broth MIC and time-kill against nine pneumococci with varying susceptibility to penicillin.
Materials and methods
Pneumococcal strains tested are listed in 
Time-kill studies were performed as described previously.
22 Viability counts were performed at 0, 2, 4, 6, 12 and 24 h. Assays were analysed by determining the number of strains that yielded a l o g 1 0 cfu/mL of -1, -2 and 3, respectively, relative to counts at time 0 h, for all compounds at all time periods. Antimicrobial agents were considered bactericidal at the lowest concentration that reduced the original inoculum by 3 log 10 cfu/mL (99.9%), and bacteriostatic if the inoculum was reduced by 0-3 log 10 cfu/mL. Antibiotic carry-over was addressed as described previously.
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Results
Broth MICs (mg/L) of the nine strains tested are presented in Table I Results of time-kill tests are presented in Table II . All -lactams were bactericidal at the MIC after 24 h, and yielded 90% killing after 12 h at concentrations above the MIC. Bactericidal concentrations of cefditoren, even for penicillin-resistant strains, were 0.5 mg/L at 24 h. Additionally, cefditoren and WY-49605 were the only compounds that killed 99% of all strains after 6 h at 4 MIC. Cefditoren and amoxycillin killed 90% of all strains at 8 MIC, and WY-49605 at 4 MIC, after 4 h. Ampicillin had time-kill kinetics similar to those of amoxycillin, but MICs were 1-2 dilutions higher than the latter drug. Cefuroxime and cefpodoxime were the most active of the other oral cephalosporins tested. The figure graphically Table III compares MIC and time-kill data obtained in the current study with previously published peak human serum levels of oral -l a c t a m s . 
Discussion
Cefditoren (ME-1207) is a new oral cephalosporin in pivaloyloxymethyl ester form with improved activity against staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae and some Enterobacteriaceae and Gram-negative non-fermenters. Cefditoren is stable against various -lactamases except those from Providencia rettgeri, Burkholderia cepacia and some Escherichia coli strains. 26, 27 MICs of cefditoren against penicillinsusceptible, intermediate and penicillin-resistant pneumococci have been shown, both by us 13 and by workers in France 28 and Spain, 29 to be the lowest of all oral -lactams against these strains. The current results confirm preliminary time-kill studies which documented the superior antipneumococcal activity of cefditoren compared with cefuroxime and cefpodoxime. 29 Cefditoren had MICs, even against penicillin-resistant strains, 0.5 mg/L, with maximal bacteriostatic and bactericidal values after 24 h of 0.5 mg/L against the latter group of strains. Additionally, cefditoren seems to possess a similar or slightly lower selective capability than cefotaxime to select for penicillin-resistant pneumococci in vitro. 30 The superior activity of amoxycillin and WY-49605 compared with other oral -lactams other than cefditoren, and superior activity of cefuroxime, cefpodoxime and cefdinir compared with cefaclor and cefixime, shown by time-kill curves in our study, confirm results of MIC testing. [15] [16] [17] [18] [19] 28 However, cefditoren and WY-49605 produced lower MICs, and were bactericidal at lower concentrations, than other -lactams tested. Because of the activity of cefditoren and WY-49605 against these organisms, there is a need for established clinically relevant breakpoints for these agents, as has been achieved for amoxycillin and cefuroxime axetil.
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There is currently no agreement on therapy of otitis media caused by penicillin-intermediate and -resistant pneumococci. Amoxycillin is the treatment of choice for susceptible and intermediate strains, but its role in the treatment of otitis media caused by penicillin-resistant strains is still under investigation. 10 Pending results of toxicological and pharmacokinetic studies, cefditoren and WY-49605 may prove to be a valuable alternative for the treatment of this condition. 
